OBJECTIVES: The primary objective of this study was to determine the bifidogenic effect of galacto-oligosaccharides (GOS) in a follow-on formula and the effects on other intestinal bacteria. Secondary objectives were the effects on stool characteristics, growth, and general well-being. PARTICIPANTS AND METHODS: In a multicenter, double-blind study, 159 healthy infants, formula-fed at enrollment (at 4-6 months), were randomized to an experimental follow-on formula supplemented with 5 g/L (GOS) (77 infants), or to a standard follow-on formula (control, 82 infants). Infants were evaluated at enrollment (study day 1 = sd1), after 6 weeks (study day 2 = sd2), and after an additional 12 weeks (study day 3 = sd3). At each study day, a fresh stool sample for the bacterial counts was collected, and the growth parameters were measured. At sd2, urinary specimens were collected for the evaluation of urinary osmolarity. RESULTS: At sd2 and sd3, the GOS group had a higher median number (colony-forming units per gram of stool) of bifidobacteria than did the control group (sd2 GOS 9.2 x 10(9) vs control 4.4 x 10(9), P = 0.012); (sd3 GOS 7.2 x 10(9) vs control 2.4 x 10(9), P = 0.027). Other bacteria did not show any significant differences between the 2 groups at all study days. The GOS produced softer stools but had no effect on stool frequency. The urinary osmolarity (mOsm/L) at sd2 was comparable in both groups. Supplementation had no influence on the incidence of gastrointestinal side effects or on the growth of the infants. CONCLUSIONS: These data indicate that the addition of GOS (5 g/L) to a follow-on formula positively influences the bifidobacteria flora and the stool consistency in infants during the supplementation period at weaning. No local or systemic side effects were recorded.
RCT Entities:
OBJECTIVES: The primary objective of this study was to determine the bifidogenic effect of galacto-oligosaccharides (GOS) in a follow-on formula and the effects on other intestinal bacteria. Secondary objectives were the effects on stool characteristics, growth, and general well-being. PARTICIPANTS AND METHODS: In a multicenter, double-blind study, 159 healthy infants, formula-fed at enrollment (at 4-6 months), were randomized to an experimental follow-on formula supplemented with 5 g/L (GOS) (77 infants), or to a standard follow-on formula (control, 82 infants). Infants were evaluated at enrollment (study day 1 = sd1), after 6 weeks (study day 2 = sd2), and after an additional 12 weeks (study day 3 = sd3). At each study day, a fresh stool sample for the bacterial counts was collected, and the growth parameters were measured. At sd2, urinary specimens were collected for the evaluation of urinary osmolarity. RESULTS: At sd2 and sd3, the GOS group had a higher median number (colony-forming units per gram of stool) of bifidobacteria than did the control group (sd2 GOS 9.2 x 10(9) vs control 4.4 x 10(9), P = 0.012); (sd3 GOS 7.2 x 10(9) vs control 2.4 x 10(9), P = 0.027). Other bacteria did not show any significant differences between the 2 groups at all study days. The GOS produced softer stools but had no effect on stool frequency. The urinary osmolarity (mOsm/L) at sd2 was comparable in both groups. Supplementation had no influence on the incidence of gastrointestinal side effects or on the growth of the infants. CONCLUSIONS: These data indicate that the addition of GOS (5 g/L) to a follow-on formula positively influences the bifidobacteria flora and the stool consistency in infants during the supplementation period at weaning. No local or systemic side effects were recorded.
Authors: Maria Quintero; Maria Maldonado; Mariaelisa Perez-Munoz; Roberto Jimenez; Terry Fangman; John Rupnow; Anja Wittke; Michael Russell; Robert Hutkins Journal: Curr Microbiol Date: 2011-02-04 Impact factor: 2.188
Authors: María José Bernal; María Jesús Periago; Rosario Martínez; Inmaculada Ortuño; Manuel Sánchez-Solís; Gaspar Ros; Fernando Romero; Pedro Abellán Journal: Eur J Pediatr Date: 2013-06-29 Impact factor: 3.183
Authors: Melinda A Engevik; Heather A Danhof; Anne Hall; Kristen A Engevik; Thomas D Horvath; Sigmund J Haidacher; Kathleen M Hoch; Bradley T Endres; Meghna Bajaj; Kevin W Garey; Robert A Britton; Jennifer K Spinler; Anthony M Haag; James Versalovic Journal: BMC Microbiol Date: 2021-05-24 Impact factor: 3.605
Authors: Claude Ashley; William H Johnston; Cheryl L Harris; Suzanne I Stolz; Jennifer L Wampler; Carol Lynn Berseth Journal: Nutr J Date: 2012-06-07 Impact factor: 3.271
Authors: Chia-Chien Hsieh; Blanca Hernández-Ledesma; Samuel Fernández-Tomé; Valerie Weinborn; Daniela Barile; Juliana María Leite Nobrega de Moura Bell Journal: Biomed Res Int Date: 2015-02-19 Impact factor: 3.411
Authors: Mary N Mugambi; Alfred Musekiwa; Martani Lombard; Taryn Young; Reneé Blaauw Journal: BMC Med Res Methodol Date: 2013-11-13 Impact factor: 4.615